Interaction of Vitamin D and Tumor Necrosis Factor-α can modulate the Outcomes of ICSI

Ali A. Bendary¹, Yasmin M. Marei² and Walid Mohamed Elnagar³

Department of ¹Obstetrics & Gynecology, ²Medical Biochemistry Faculty of Medicine, Benha University, ³Obstetrics & Gynecology, Faculty of Medicine, Zagazig University, Egypt

ABSTRACT

Objective: To investigate the relation between vitamin D sufficiency (VDS) levels and outcomes of ICSI for infertile women.

Materials and Methods: 104 infertile women were clinically evaluated and given blood samples for estimation of serum levels of tumor necrosis factor-α (TNF-α) and 25-Hydroxy VD (25-OHVD) and were categorized according to VDS levels. All women underwent frozen embryo transfer after controlled ovarian stimulation. The chemical (CPR) and clinical pregnancy rates (CLPR), the early pregnancy loss (EPL), and the successful pregnancy rate (SPR) were evaluated concerning the estimated levels of 25-OHVD and TNF-α.

Results: The CPR was 53.8% and was higher among VD deficient (VDD) women. The CLPR was 36.5% and showed an insignificant difference according to VDS status. The EPR was 20.2%, while the SPR was 16.3% and was significantly higher in VDS than in VDD women. There was a negative significant correlation between serum levels of 25-OHVD and TNF-α. The CPR and CLPR showed negative significant correlations with serum TNF-α levels. The SPR showed positive and negative significant correlations with serum levels of 25-OHVD and TNF-α, respectively.

Conclusion: VD might improve ICSI outcomes through its modulatory action on the systemic inflammatory milieu. Pro-inflammatory cytokines had deleterious effects on ICSI outcomes and the balance between pre- and anti-inflammatory cytokines must be corrected before committing ART procedures.

Key Words: Early pregnancy loss, ICSI, successful outcome, tumour necrosis factor-α, Vitamin D

Received: 01 January 2023, Accepted: 14 January 2023

Corresponding Author: Ali A. Bendary, MD, Department of Obstetrics & Gynecology, Faculty of Medicine, Benha University, Egypt, Tel.: 01006768003, E-mail: bendary2021@gmail.com

ISSN: 2090-7265, August 2023, Vol.13, No. 3

INTRODUCTION

Vitamin D (VD) is a secosteroid, which is derived from cholesterol and has a vital role in the maintenance of human health with multiple extra-skeletal effects[1]. Serum VD is essential for both the mother's and the fetus's health and its deficiency can increase the risk of fetal abnormalities including fetal heart abnormalities[2]. Maternal VD deficiency (VDD) was found to be associated with adverse maternal outcomes and an increased risk of pregnancy complications[3] and causes placental dysplasia with subsequent intrauterine growth retardation[4].

Vitamin D acting on VD receptor (VDR), which showed widespread distribution almost in all immune cells, induces inhibition of the production of pro-inflammatory cytokines[5], reduction of the antigen-presenting capacity and T-cell stimulatory ability by antigen-presenting cells[6] with upregulation of regulatory T cells and the promotion of the shift of Th1 towards the Th2 cells with its regulatory anti-inflammatory actions[7].

Tumor necrosis factor-alpha (TNF-α) is a homotrimer of 17 kDa protein consisting of 157 amino acids and is mainly produced by activated macrophages, T lymphocytes, and natural killer cells[8]. TNF-α has potent inflammatory and apoptotic actions[9].

Inflammatory cytokines showed intimate relation to female infertility and deliriously affected the outcomes of assisted reproductive technology (ART) and its high concentrations in follicular fluid affect the development and fertilization of oocytes[10]. Activated TNF-α signaling due to restraint stress and elevation of levels of corticotrophin-releasing hormone impair oocyte competence and affect fertility and outcomes of ART[11].

Objectives:

This study tried to assess the impact of VDS state on outcomes of ICSI for infertile women

Design:

Prospective interventional non-randomized comparative study
Interaction of Vitamin D and TNF-α & the Outcomes of ICSI

Setting:

Department of Obstetrics & Gynecology, Faculty of Medicine, Benha and Zagazig Universities, in conjunction with multiple private centers Benha, Cairo and Zagazig; Egypt

Ethical considerations:

The preliminarily approval of the study protocol was obtained from department of obstetrics and gynecology, Faculty of medicine, Zagazig University and after the completion of case collection the final approval of the study protocol was obtained from the Local Ethical Committee. All women who fulfilled the inclusion criteria were asked to sign the written fully informed consent after a discussion of the study protocol with the author.

Blindness:

The collected samples were sent to clinical pathologists as numbered innominate samples without clinical diagnosis or indication for estimation of VD. On the other side, the obstetrician was also blinded about the results of VD level estimations till the end of the study. Thereafter, the results of lab work and ICSI outcomes were interpreted against each other.

PATIENTS AND METHODS

All infertile women attending the clinics of ART were evaluated clinically, and by ultrasonographic examination and had lab investigations essential for the diagnosis and preparation if included in the study.

Exclusion criteria

Age older than 40 years, infertility secondary to endocrinopathy, congenital malformation, exposure to radio-or chemotherapy, ovarian or uterine diseases, obesity grade II with body mass index (BMI) >35 kg/m2 to guard against the effect of obesity of serum levels of the studied parameters, attendance during winter session to exclude the seasonal effects on VD levels or refusal to participate in the study.

Inclusion criteria

Infertile women assigned and prepared for frozen embryo transfer, free of the exclusion criteria, and signed the written fully informed consent to participate in the study and undergo the assigned investigation and receive the appropriate therapies were included in the study. Ten fertile women with age- and BMI cross-matched to the included infertile women and free of inclusion and exclusion criteria were enrolled as a control group for the study investigations.

Evaluation of VD sufficiency status:

The enrolled women were graded according to the estimated serum 25-hydroxy vitamin D (25-OHVD) as having VDS, insufficiency, or VDD if serum 25-OHVD levels were ≥75 nmol/L, 50-75 nmol/L or <50 nmol/L, respectively. Women who had VDD were categorized as mild, moderate, and severe VDD if 25-OHVD serum levels were 25-50 nmol/L, 12.5-25 nmol/L, and <12.5 nmol/L, respectively[12].

Laboratory investigations

Blood samples were obtained at the time of clinic attendance under complete aseptic conditions, and after clotting centrifuged for 10-min at 3000 rpm, and the separated serum was stored at -80°C till ELISA assayed for estimation of serum levels of human 25-OHVD[13] and human TNF-α[14] using ELISA kit (Abcam Inc., San Francisco, USA; catalog no. ab213966, ab46087).

Study protocol

Ovarian stimulation protocol was provided according to hospital guidelines using the gonadotrophin-releasing hormone (GnRH) flexible antagonist protocol in the form of daily subcutaneous injection of 300-450 IU of Gonal F (75 IU; 5.5µg, Merck Serono Ltd, UK) starting on the 2nd day of the cycle and cetrorelix (Cetrotide®, Merck, Germany) 250 µg daily was started when the dominant follicle reached 14 mm till the triggering day. Two ampoules of triptorelin acetate (Decapeptyl, Ferring Pharmaceuticals Ltd., Wittland, Germany; 0.1 mg, subcutaneous injection) was given as triggering when the mean diameter of the leading follicle reached ≥18 mm or >3 follicles reached a mean diameter of ≥16 mm. TVU-guided oocyte retrieval was performed 36 hours later and fertilization was carried out by intracytoplasmic sperm injection (ICSI).

The day-3 embryos are graded as good (G grade) if it contains 6-9 symmetric cells with no fragmentation, as fair (F grade) if cells are symmetric but there is only minor fragmentation and as poor (P grade) if cells are asymmetric with no or moderate fragmentation[15].

On the 2nd day of the cycle estradiol valerate (Progonova, 2 mg, Bayer Schering Pharma, UK) was given in a dose of 6 mg, and higher doses were gradually started till endometrial thickness was ≥8 mm, wherein the progesterone therapy was started as intra-vaginal progesterone (promostig 400mg progesterone vaginal supp, IBSA, Switzerland, once daily) and embryo transfer was performed 5-days later. Progesterone therapy was continued till the blood pregnancy test was performed 14 days later and the chemical pregnancy rate was recorded. Pregnancy was assured by abdominal US imaging to detect a viable gestational sac and a clinical pregnancy rate was
registered. Progesterone therapy started as luteal phase support and was continued till the 10th gestational week.

**Study outcome**

The study outcome is the relation between serum levels of 25-OHVD and TNF-α that were estimated at enrolment and the chemical and clinical pregnancy rates, the rates of early pregnancy loss that was defined as pregnancy loss before the 12th gestational week (GW), and successful pregnancy rate, which is defined as the frequency of women continued their pregnancy after the 12th GW.

**Statistical analysis:**

The obtained data were analyzed using One-way ANOVA and Chi-square (X² test) tests. Pearson's correlation analysis was applied to evaluate correlations between at-enrolment serum levels of 25-OHVD and TNF-α and ICSI outcomes using the IBM® SPSS® Statistics (Version 22, 2015; Armonk, USA) for Windows statistical package. *P* value <0.05 was considered statistically significant.

**RESULTS**

The study included 104 infertile women after excluding 18 women for having uterine anomalies (n=2), obesity of grade II (n=7), endocrinopathy (n=4), and autoimmune disorders (n=5). Enrolment data of these 104 women are shown in (Table 1).

**Table 1: Enrolment data of studied infertile women**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
</tr>
<tr>
<td>&lt;25</td>
<td>4 (3.8%)</td>
</tr>
<tr>
<td>25-30</td>
<td>27 (26%)</td>
</tr>
<tr>
<td>&gt;30-35</td>
<td>43 (41.4%)</td>
</tr>
<tr>
<td>&gt;35</td>
<td>30 (28.8%)</td>
</tr>
<tr>
<td>Total</td>
<td>32.3±4.2</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td></td>
</tr>
<tr>
<td>Overweight (&lt;30)</td>
<td>37 (35.6%)</td>
</tr>
<tr>
<td>Obese I (&gt;30-34.99)</td>
<td>67 (64.4%)</td>
</tr>
<tr>
<td>Total</td>
<td>31.3±1.8</td>
</tr>
<tr>
<td>Blood pressure measures (mmHg)</td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>117.5±3.4</td>
</tr>
<tr>
<td>Diastolic</td>
<td>83.9±3.2</td>
</tr>
<tr>
<td>Random blood glucose (mg/dl)</td>
<td>97.3±9.9</td>
</tr>
</tbody>
</table>

The mean serum 25-OHVD estimated in all studied samples was 44.63±22.3; range: 8.3-80.5 nmol/L and was significantly (*P*<0.001) lower than the level estimated in control samples (79.32±2.22; range: 76.4-83.4 nmol/L). Estimated serum 25-OHVD level was sufficient in 12 samples (11.5%), insufficient in 41 samples (39.5%), and deficient in 51 samples (49%), (Fig. 1).
Further, the estimated 25-OHVD level in samples of women had VDD indicated mild, moderate and severe VDD in 23, 16 and 12 samples, respectively as shown in (Figure 2).

Fig. 2: Patients' distribution among VD sufficiency statuses with mean levels of 25-OHVD estimated in samples of each category

Serum levels of TNF-α estimated in patients' samples (3.3±0.63 ng/ml) were significantly ($p<0.001$) higher in comparison to levels estimated in control samples (1.9±0.47 ng/ml). Serum levels of TNF-α estimated in samples of patients who had SVD were non-significantly ($p=0.144$) lower, while were significantly ($p=0.029$) lower in comparison to levels estimated in samples of patients who had insufficient VD and VDD, respectively with non-significantly high levels estimated in samples of patients had VDD than samples of patients had VD insufficiency (Fig. 3).

Fig. 3: Mean Serum TNF-α (ng/ml) levels estimated in samples of studied women categorized according to VD sufficiency status
During the study duration, 56 women got positive pregnancy tests for a CPR rate of 53.8%; CPR among VDD women was higher with significant \((p=0.042)\) and insignificant \((P=0.777)\) differences in comparison to the rate detected among women who had VD insufficiency and sufficiency, respectively, with non-significant \((p=0.302)\) difference in favor of women had SVD. Thirty-eight women (67.9\%) of the 56 women who had positive chemical pregnancies developed positive clinical pregnancies for a CLPR rate of 36.5\% among the total study population. Women who had SVD had non-significantly higher CLPR compared to women who had insufficient \((p=0.972)\) and deficient \((p=0.768)\) VD levels with non-significant \((p=0.724)\) differences in favor of women who had insufficient VD levels.

Unfortunately, 21 women (55.3\%) of those who had clinical pregnancy, developed EPL for a rate of 20.2\% among total women. The successful pregnancy rate of women who had clinical pregnancies was 44.7\% and 16.3\% among total enrolled women. The SPR among women who had SVD was higher with a significant \((P=0.033)\) difference than the rate reported in VDD women and was non-significant \((P=0.094)\) compared to the rate among women who had VD insufficiency who showed non-significantly \((P=0.092)\) higher successful pregnancy rate than VDD women (Table 2, Fig. 4).

<table>
<thead>
<tr>
<th>Variables</th>
<th>Sufficiency (n=12)</th>
<th>Insufficiency (n=41)</th>
<th>Deficiency (n=51)</th>
<th>Total (n=104)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive chemical pregnancy rate*</td>
<td>7 (58.3%)</td>
<td>17 (41.5%)</td>
<td>32 (62.7%)</td>
<td>56 (53.8%)</td>
</tr>
<tr>
<td>Positive clinical pregnancy rate†</td>
<td>5 (71.4%)</td>
<td>12 (70.6%)</td>
<td>21 (41.2%)</td>
<td>38 (67.9%)</td>
</tr>
<tr>
<td>Early pregnancy loss rate‡</td>
<td>1 (20%)</td>
<td>5 (41.7%)</td>
<td>15 (71.4%)</td>
<td>21 (55.3%)</td>
</tr>
<tr>
<td>Successful pregnancy rate‡</td>
<td>4 (80%)</td>
<td>7 (58.3%)</td>
<td>6 (28.6%)</td>
<td>17 (44.7%)</td>
</tr>
</tbody>
</table>

* \% was calculated concerning the total enrolled women  
† \% was calculated concerning the number of women who had positive chemical pregnancy  
‡ \% was calculated concerning the number of women who had a positive clinical pregnancy

Fig. 4: Patients distributions according to ICSI outcomes among VD sufficiency statuses
Pearson's correlation analysis showed a negative significant ($r=-0.347, p<0.001$) correlation between serum levels of 25-OHVD and TNF-α that were estimated at enrolment (Fig. 5). The CPR and CLPR showed positive non-significant correlations with at-enrolment serum 25-OHVD levels, while showed negative significant correlations with at enrolment Serum TNF-α levels.

The EPL rate showed non-significant correlations with serum levels of both markers but this correlation was negative with 25-OHVD and positive with TNF-α. However, the SPR showed a positive significant correlation with serum 25-OHVD, but the relation with serum level of TNF-α was negatively significant (Table 3).

<table>
<thead>
<tr>
<th>Variables</th>
<th>Serum 25-OHVD level</th>
<th>Serum TNF-α level</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$r$</td>
<td>$p$</td>
</tr>
<tr>
<td>Chemical pregnancy rate</td>
<td>0.034</td>
<td>0.734</td>
</tr>
<tr>
<td>Clinical pregnancy rate</td>
<td>0.057</td>
<td>0.565</td>
</tr>
<tr>
<td>The early pregnancy loss rate</td>
<td>0.142</td>
<td>0.149</td>
</tr>
<tr>
<td>Successful pregnancy rate</td>
<td>0.197</td>
<td>0.045</td>
</tr>
</tbody>
</table>

DISCUSSION

At-enrolment serum 25-OHVD concentration indicated VD sufficiency in only 11.5% of the studied women, while 49% had VDD; a finding indicated a high prevalence of hypovitaminosis D among women seeking pregnancy. These figures are in hand with previous studies documenting the high prevalence of VDD among infertile women[17-19].

The relation between 25-OHVD serum levels and ICSI outcomes was wave-like relation, where higher CPR was reported among women who had VDD however these VDD women showed the highest EPL rate. Similarly, a previous study detected higher miscarriage rates in women who had low serum VD concentration[20]. On the other side, women who had insufficient-to-sufficient VD concentrations showed lower CPR but also showed lower EPL and higher SPR. Further, correlation analysis showed non-significant relation between serum 25-OHVD and CPR, CLPR, and EPL rates while showing significant relation to SPR.

In line with this discrepant relation between 25-OHVD levels and ICSI outcomes, a recent study detected positive relation between serum and follicular fluid VD levels on one side and follicular fluid VD concentrations with total and MII oocyte counts, positive pregnancy test, and CLPR, but it does not correlate with miscarriage rate[21].
On contrary, another recent study found no relation between serum VD levels and oocyte count or maturation rate but detected a relation between fertility and clinical pregnancy rates\cite{22}.

However, the obtained results assured a possible relation between VD sufficiency and successful pregnancy after ICSI as evidenced by the results of the correlation analysis. In support of the role of VD sufficiency during IVF procedures, one study detected higher pregnancy rate during IVF procedures in women showing higher endometrial VD receptor (VDR) expression levels, especially during the implantation window of the menstrual cycle than in women with decreased expression\cite{23}. Another study found VD supplemental therapy (VDST) increased serum vitamin D3 levels with subsequent higher implantation rates during IVF\cite{24}. Recently, a wide-population study of women undergoing ICSI detected a positive correlation between basal serum levels of 25-OHVD and basal levels of follicle-stimulating hormone, estradiol, anti-Müllerian hormone, antral follicle count, and a number of the retrieved oocytes\cite{19}.

In a trial to explain the relation between VD sufficiency and outcomes of IVF procedure, in a VDD animal model, VDST restored the competency of the progesterone receptor, upregulated the expressional response of the homeobox transcription factor-10/immunophilin FK506-binding protein 52 axis, which improves the uterine receptivity and endometrial decidualization at the time of implantation in a dose-dependent fashion\cite{25}. Another animal study found VDR pathway can modulate the expression of the homeobox A10/a10 gene which is an intrinsic component of implantation, decidualization, and immunomodulation in the adult uterus\cite{26}. Clinically, VDST for POCS infertile women improved serum VD levels with concomitant improved endometrial receptivity\cite{27}.

The current study detected a negative significant correlation between serum levels of TNF-α and both estimated levels of 25-OHVD and ICSI outcomes, thus, VD sufficiency may impact the outcomes of ICSI especially the proper implantation that allowed a higher percentage of women had successful pregnancy through its immune modulatory effect via the reduction of serum TNF-α and free levels of 25-OHVD and leucocytic count and serum levels of high-sensitivity CRP\cite{31}.

**CONCLUSION**

Vitamin D sufficiency is a prerequisite for a successful ICSI procedure. VD might exert its beneficial effects on ICSI outcomes through its modulatory action on the systemic inflammatory milieu. Pro-inflammatory cytokines had deleterious effects on ICSI outcomes and the balance between pre- and anti-inflammatory cytokines must be corrected before committing ART procedures.

**Study limitations:**

Estimation of the levels of both biomarkers in the follicular fluid and its relation to their serum levels was to be evaluated to decide as regards the use of VD supplemental therapy

**CONFLICT OF INTEREST**

There are no conflicts of interests.

**REFERENCES**


